New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor of Urologic Oncology at the University of Utah, and leading urologic oncologist ... Show More
Nov 5
Ep. 341 Understanding Overactive Bladder in Male Patients with Dr. Bilal Chughtai
How many prostate medications and procedures should a man try before anyone checks his bladder? Dr. Bilal Chughtai has met men who worked through an alpha blocker, add-on medications, a minimally invasive prostate procedure, and even resective surgery before anyone named overacti ... Show More
40m 42s
Nov 3
Ep. 340 Understanding Intermediate-Risk Bladder Cancer with Dr. Wesley Yip
By one estimate, half or more of all non-muscle invasive bladder cancer (NMIBC) is intermediate risk, yet the major guidelines still do not define it the same way, which leaves urologists sorting a large, mixed group of patients without a shared playbook for when to resect again, ... Show More
43m 42s
Oct 29
Ep. 339 AI's Role in Enhancing Urology Care with Dr. David Canes
By his own estimate, an AI scribe gives one urologist about two hours of his day back, and an evidence tool built into it has taught him something new in the clinic almost every day. On this episode of BackTable Urology, Dr. Ruchika Talwar welcomes back Dr. David Canes, urologist ... Show More
58m 27s
Oct 2022
Dr Thomas Seisen talks about treatment options for metastatic UTUC
<p>During this episode, Dr. Thomas Seisen (FR), an associate member on the EAU Guidelines Panel for Non-Muscle Invasive Bladder Cancer, answers questions about metastatic upper urothelial cancer (UTUC) treatment options in the 2022 guidelines:</p><ul><li>What are the systemic tr ... Show More
17m 11s
